Tobramycin Ophthalmic Solution, USP 0.3% Rx Only

Manufacturer
Sandoz Inc
Effective date
2021-08-31
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
8
Source
full-release
Hydrated at
2026-05-31 20:39:55

Label at a glance#

ProductTobramycin
Active ingredientTOBRAMYCIN
Label structure11 sections

Indications and uses

Tobramycin ophthalmic solution, 0.3% is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of tobramycin ophthalmic solution, 0.3%. Clinical studies have shown tobramycin to be safe and effective for use in children.

Dosage and administration

In mild to moderate disease, instill 1 or 2 drops into the affected eye(s) every 4 hours. In severe infections, instill 2 drops into the eye(s) hourly until improvement, following which treatment should be reduced prior to discontinuation.

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Tobramycin ophthalmic solution, USP 0.3% is a sterile topical ophthalmic antibiotic formulation prepared specifically for topical therapy of external ophthalmic infections.

Each mL of tobramycin ophthalmic solution, USP 0.3% contains: Active: tobramycin 0.3% (3 mg). Preservative: benzalkonium chloride 0.01% (0.1 mg). Inactives: boric acid, sodium sulfate, sodium chloride, tyloxapol, sodium hydroxide and/or sulfuric acid (to adjust pH) and purified water. Tobramycin ophthalmic solution, USP 0.3% has a pH range between 7.0 and 8.0 and an osmolality of 260-320 mOsm/kg.

Tobramycin is a water-soluble aminoglycoside antibiotic active against a wide variety of gram-negative and gram-positive ophthalmic pathogens.

The chemical structure of tobramycin is:

chemical
chemical

MW=467.52

Molecular Formula: C18H37N5O9

Chemical Name: 0-{3-amino-3-deoxy-α-D-gluco-pyranosyl-(1→4)} -0- {2,6-diamino-2,3,6-trideoxy-α-D-ribohexopyranosyl-(1→6) }-2-deoxystreptamine.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

In Vitro Data

In vitro studies have demonstrated tobramycin is active against susceptible strains of the following microorganisms: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains.

Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae.

Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. Bacterial susceptibility studies demonstrate that in some cases, microorganisms resistant to gentamicin retain susceptibility to tobramycin.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Tobramycin ophthalmic solution, 0.3% is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of tobramycin ophthalmic solution, 0.3%. Clinical studies have shown tobramycin to be safe and effective for use in children.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Tobramycin ophthalmic solution, 0.3% is contraindicated in patients with known hypersensitivity to any of its components.

WARNINGS

WARNINGS SECTION

FOR TOPICAL OPHTHALMIC USE. NOT FOR INJECTION INTO THE EYE. Sensitivity to topically applied aminoglycosides may occur in some patients. Severity of hypersensitivity reactions may vary from local effects to generalized reactions such as erythema, itching, urticaria, skin rash, anaphylaxis, anaphylactoid reactions, or bullous reactions. If a sensitivity reaction to tobramycin ophthalmic solution, 0.3% occurs, discontinue use.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

As with other antibiotic preparations, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, appropriate therapy should be initiated. Cross-sensitivity to other aminoglycoside antibiotics may occur; if hypersensitivity develops with this product, discontinue use and institute appropriate therapy. Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial ocular infection.

Information for Patients

INFORMATION FOR PATIENTS SECTION

Do not touch dropper tip to any surface, as this may contaminate the solution.

Pregnancy

PREGNANCY SECTION

Reproduction studies in 3 types of animals at doses up to 33 times the normal human systemic dose have revealed no evidence of impaired fertility or harm to the fetus due to tobramycin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers

NURSING MOTHERS SECTION

Because of the potential for adverse reactions in nursing infants from tobramycin ophthalmic solution, 0.3%, a decision should be made whether to discontinue nursing the infant or discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in pediatric patients below the age of 2 months has not been established.

Geriatric Use

GERIATRIC USE SECTION

No overall clinical differences in safety or effectiveness have been observed between elderly and younger patients.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The most frequent adverse reactions to tobramycin ophthalmic solution, 0.3% are hypersensitivity and localized ocular toxicity, including lid itching and swelling, and conjunctival erythema. These reactions occur in less than three of 100 patients treated with tobramycin ophthalmic solution, 0.3%.

To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Postmarketing Experience

Additional adverse reactions identified from post-marketing use include anaphylactic reaction, Stevens-Johnson syndrome, and erythema multiforme.

The following additional adverse reactions have been reported with systemic aminoglycosides: Neurotoxicity, ototoxicity and nephrotoxicity have occurred in patients receiving systemic aminoglycoside therapy. Aminoglycosides may aggravate muscle weakness in patients with known or suspected neuromuscular disorders, such as myasthenia gravis or Parkinson’s disease, because of their potential effect on neuromuscular function.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

In mild to moderate disease, instill 1 or 2 drops into the affected eye(s) every 4 hours. In severe infections, instill 2 drops into the eye(s) hourly until improvement, following which treatment should be reduced prior to discontinuation.

HOW SUPPLIED

HOW SUPPLIED SECTION

Tobramycin ophthalmic solution, USP 0.3% is supplied as a 5 mL sterile solution, packaged in a 8 mL white plastic bottle with a plastic dispensing plug and white plastic closure as follows:

  1. 5 mL containing tobramycin 0.3% (3 mg/mL) NDC 61314-643-05

Storage

Store at 2° to 25°C (36° to 77°F).

After opening, tobramycin ophthalmic solution, USP 0.3% can be used until the expiration date on the bottle.

SPL UNCLASSIFIED SECTION

Manufactured by Alcon Laboratories, Inc.
Fort Worth, Texas 76134 for
Sandoz Inc., Princeton, NJ 08540

Revised: August 2021

300049864-0821

PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 61314-643-05

Tobramycin
Ophthalmic
Solution, USP
0.3%
Rx only

STERILE
5 mL

SANDOZ

5mlcarton
5mlcarton

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
313415tobramycin 0.3 % Ophthalmic SolutionPSN8
313415tobramycin 3 MG/ML Ophthalmic SolutionSCD8
313415tobramycin 0.3 % Ophthalmic SolutionSY8

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
TOBRAMYCIN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
f297c7c1-845a-4369-8c02-c51b92d6ae8eProduct name320240725
551d952d-4ce2-24f0-9ab0-630ad9aae596Product name220231211
362d7abb-94e6-4c60-9a58-266894157713Product name120231023
941f67d9-7f03-56d2-750c-36de24f654dbProduct name320221117
9cfa145f-dbe9-bc02-83c2-692786ef6676Product name920210928
2f9713b8-5e7e-bbcc-b364-1b2c27a63796Product name420210903
32a533bc-01c7-2b9f-bbf7-ecfb0d964277Product name420210625
9f5124fb-08b0-4c3e-8e12-a1a6ff310cbaProduct name120150309
745a62af-e1c0-4ca3-6d6e-2b6455b903beProduct name120140508
9ea85abb-fa68-5da6-ab60-2c7eef579000Product name120140508
aa1cd319-ece7-51f7-3a9d-52a64f5f4e81Product name120140508
d029211e-5e6b-725f-3696-ac6ff77da222Product name120140508
ef5b7aed-2b01-3ba8-5a1c-3bc9c9f03bb1Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
61314-643-05Tobramycin5 mL in 1 BOTTLE, PLASTICSOLUTION58

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
61314-643TOBRAMYCIN SOLUTION [SANDOZ INC]8Current NDC, Legacy NDC, 1 package rows20220205_27e2c16e-19b0-4745-93eb-5cf99f94bb92.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
61314-643-05ML - Milliliter61314-643ad46b3e1-9505-4f45-b1e6-ed32d0b6866412012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
TOBRAMYCINACTIVE INGREDIENTVZ8RRZ51VK3
TOBRAMYCINACTIVE MOIETYVZ8RRZ51VK3
BENZALKONIUM CHLORIDEINACTIVE INGREDIENTF5UM2KM3W73
BORIC ACIDINACTIVE INGREDIENTR57ZHV85D43
SODIUM CHLORIDEINACTIVE INGREDIENT451W47IQ8X3
SODIUM HYDROXIDEINACTIVE INGREDIENT55X04QC32I3
SODIUM SULFATEINACTIVE INGREDIENT0YPR65R21J3
SULFURIC ACIDINACTIVE INGREDIENTO40UQP6WCF3
TYLOXAPOLINACTIVE INGREDIENTY27PUL9H563
WATERINACTIVE INGREDIENT059QF0KO0R3

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 9 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
61314-64361314-643-05

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 9 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 14 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
BORIC ACIDBORIC ACIDR57ZHV85D4SOLUTION / OPHTHALMIC60 mgExact identifier — unii+route+dosage form
2 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XSOLUTION / OPHTHALMIC13 mgExact identifier — unii+route+dosage form
2 equally ranked IID candidates
SODIUM SULFATESODIUM SULFATE0YPR65R21JSOLUTION / OPHTHALMIC0.14 %w/vExact identifier — unii+route+dosage form
2 equally ranked IID candidates
TYLOXAPOLTYLOXAPOLY27PUL9H56SOLUTION / OPHTHALMIC5 mgExact identifier — unii+route+dosage form
2 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XSOLUTION / OPHTHALMIC13 mgExact identifier — unii+route+dosage form
2 equally ranked IID candidates
BENZALKONIUM CHLORIDEBENZALKONIUM CHLORIDEF5UM2KM3W7SOLUTION / OPHTHALMIC2 %w/vExact identifier — unii+route+dosage form
2 equally ranked IID candidates
TYLOXAPOLTYLOXAPOLY27PUL9H56SOLUTION / OPHTHALMIC5 mgExact identifier — unii+route+dosage form
2 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / OPHTHALMIC0.05 %w/vExact identifier — unii+route+dosage form
2 equally ranked IID candidates
SODIUM SULFATESODIUM SULFATE0YPR65R21JSOLUTION / OPHTHALMIC0.14 %w/vExact identifier — unii+route+dosage form
2 equally ranked IID candidates
SULFURIC ACIDSULFURIC ACIDO40UQP6WCFSOLUTION / OPHTHALMIC0.02 %w/wExact identifier — unii+route+dosage form
2 equally ranked IID candidates
BORIC ACIDBORIC ACIDR57ZHV85D4SOLUTION / OPHTHALMIC60 mgExact identifier — unii+route+dosage form
2 equally ranked IID candidates
BENZALKONIUM CHLORIDEBENZALKONIUM CHLORIDEF5UM2KM3W7SOLUTION / OPHTHALMIC2 %w/vExact identifier — unii+route+dosage form
2 equally ranked IID candidates
SULFURIC ACIDSULFURIC ACIDO40UQP6WCFSOLUTION / OPHTHALMIC0.02 %w/wExact identifier — unii+route+dosage form
2 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / OPHTHALMIC0.05 %w/vExact identifier — unii+route+dosage form
2 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A062535-001TOBREXTOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-13

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A062535-001AT

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-1384e616aacf4f…
2026-08-18 06:07:402026-07A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-13caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-13011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-1331067a03dcf5…
2025-08-23 18:47 UTC2025-08A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-136a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-13fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-13b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-1303ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-132680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-135bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-13d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-13d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-1379d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-13301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-131e350fbaab3a…
2024-05-31 18:47 UTC2024-05A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-138072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-135c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-135d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-134b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-1374a2ff9319b5…
2022-03-09 01:35 UTC2022-03A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-13bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-13782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-1387673890dc5c…
2021-03-12 10:30 UTC2021-03A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-135aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-138869cabd3fbd…
2020-11-12 02:37 UTC2020-11A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-13c0c555d07b60…
2019-12-14 00:12 UTC2019-12A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-133f01610625f2…
2019-09-15 20:21 UTC2019-09A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-13b00525d2431f…
2019-07-19 19:46 UTC2019-07A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-13ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-136a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-131c564ffb4f44…
2023-12-20 04:57 UTC2023-12A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-13ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-13a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-139b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-13a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-133f0d92c62455…
2023-05-13 08:27 UTC2023-05A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-13053a50430f4f…
2023-01-26 05:58 UTC2023-01A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-133bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-133a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A062535-001TOBREX0.3%SOLUTION/DROPS / OPHTHALMICAT1984-12-13f41ea6bd6efb…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A062535-001AT184e616aacf4f…
2026-08-18 06:07:402026-07A062535-001AT1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A062535-001AT1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A062535-001AT131067a03dcf5…
2025-08-23 18:47 UTC2025-08A062535-001AT16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A062535-001AT1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A062535-001AT1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A062535-001AT103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A062535-001AT12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A062535-001AT15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A062535-001AT1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A062535-001AT1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A062535-001AT179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A062535-001AT1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A062535-001AT11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A062535-001AT18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A062535-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A062535-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A062535-001AT14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A062535-001AT174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A062535-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A062535-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A062535-001AT187673890dc5c…
2021-03-12 10:30 UTC2021-03A062535-001AT15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A062535-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A062535-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A062535-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09A062535-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07A062535-001AT1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A062535-001AT16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A062535-001AT11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A062535-001AT1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A062535-001AT1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A062535-001AT19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A062535-001AT1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A062535-001AT13f0d92c62455…
2023-05-13 08:27 UTC2023-05A062535-001AT1053a50430f4f…
2023-01-26 05:58 UTC2023-01A062535-001AT13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A062535-001AT13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A062535-001AT1f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
TobramycinTOBRAMYCINSandoz Inc27e2c16e-19b0-4745-93eb-5cf99f94bb922021-08-31Warnings, Adverse reactionsExact identifier
ndc (package): 61314-643-05
ndc (product): 61314-643
ndc11 (package): 61314064305
spl id: 505c82ff-86c3-4269-96cb-faae872c7539
spl set id: 27e2c16e-19b0-4745-93eb-5cf99f94bb92

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.